{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:50:09Z","timestamp":1785894609398,"version":"3.56.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005809","name":"Hyderabad Eye Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["2021-13131"],"award-info":[{"award-number":["2021-13131"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["202511074841"],"award-info":[{"award-number":["202511074841"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006464","name":"Birla Institute of Technology and Science, Pilani","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006464","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.xops.2026.101226","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:50:29Z","timestamp":1778482229000},"page":"101226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Topotecan Microneedle Scleral Patch: A Transscleral Drug Delivery Study for Retinoblastoma"],"prefix":"10.1016","volume":"6","author":[{"given":"Vishal","family":"Raval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Arawindh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharayu","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya","family":"Jakati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9686-9525","authenticated-orcid":false,"given":"Venkata Vamsi Krishna","family":"Venuganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2026.101226_bib1","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaophthalmol.2013.8001","article-title":"Retinoblastoma incidence patterns in the US surveillance, Epidemiology, and end results program","volume":"132","author":"Wong","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2026.101226_bib2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3928\/01913913-20171116-03","article-title":"Retinoblastoma in the United States: a 40-year incidence and survival analysis","volume":"55","author":"Fernandes","year":"2018","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.xops.2026.101226_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/APO.0000000000000060","article-title":"Predicted trends in the incidence of retinoblastoma in the Asia-Pacific Region","volume":"3","author":"Usmanov","year":"2014","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.xops.2026.101226_bib4","doi-asserted-by":"crossref","first-page":"e763","DOI":"10.1542\/peds.2008-0518","article-title":"Retinoblastoma: one world, one vision","volume":"122","author":"Rodriguez-Galindo","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.xops.2026.101226_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/bjo.2008.138750","article-title":"Incidence of retinoblastoma in the USA: 1975-2004","volume":"93","author":"Broaddus","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101226_bib6","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1542\/peds.112.6.1248","article-title":"Screening for retinoblastoma: presenting signs as prognosticators of patient and ocular survival","volume":"112","author":"Abramson","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.xops.2026.101226_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/IIO.0000000000000054","article-title":"Retinoblastoma: evidence for stage-based chemotherapy","volume":"55","author":"Chung","year":"2015","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.xops.2026.101226_bib8","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/archopht.1996.01100140530002","article-title":"Chemoreduction in the initial management of intraocular retinoblastoma","volume":"114","author":"Shields","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2026.101226_bib9","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/archopht.126.6.862","article-title":"The adverse events of chemotherapy for retinoblastoma: what are they? Do we know?","volume":"126","author":"Rizzuti","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2026.101226_bib10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3171\/2012.5.PEDS1277","article-title":"Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma","volume":"10","author":"Jabbour","year":"2012","journal-title":"J Neurosurg Pediatr"},{"key":"10.1016\/j.xops.2026.101226_bib11","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.ophtha.2007.12.014","article-title":"A phase I\/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results","volume":"115","author":"Abramson","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101226_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/13816810.2016.1244695","article-title":"Ophthalmic artery chemosurgery for eyes with advanced retinoblastoma","volume":"38","author":"Abramson","year":"2017","journal-title":"Ophthalmic Genet"},{"key":"10.1016\/j.xops.2026.101226_bib13","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2011.03.013","article-title":"Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis","volume":"118","author":"Suzuki","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101226_bib14","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2147\/OPTH.S43398","article-title":"Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution","volume":"7","author":"Thampi","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xops.2026.101226_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034120","article-title":"Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review","volume":"7","author":"Abramson","year":"2012","journal-title":"PLoS one"},{"key":"10.1016\/j.xops.2026.101226_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jamaophthalmol.2013.7666","article-title":"Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results","volume":"132","author":"Shields","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2026.101226_bib17","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1097\/IAE.0b013e318295f783","article-title":"Management of advanced retinoblastoma with intravenous chemotherapy then intra-arterial chemotherapy as alternative to enucleation","volume":"33","author":"Shields","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.xops.2026.101226_bib18","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/jamaophthalmol.2016.0244","article-title":"Intra-arterial chemotherapy for retinoblastoma: a systematic review","volume":"134","author":"Yousef","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2026.101226_bib19","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00247-016-3554-6","article-title":"A review of the literature for intra-arterial chemotherapy used to treat retinoblastoma","volume":"46","author":"Wyse","year":"2016","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.xops.2026.101226_bib20","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.ophtha.2018.05.013","article-title":"Ophthalmic vascular events after primary unilateral intra-arterial chemotherapy for retinoblastoma in early and recent eras","volume":"125","author":"Dalvin","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101226_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/ICU.0000000000000850","article-title":"Complications of intravitreal injections: 2022","volume":"33","author":"Patel","year":"2022","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.xops.2026.101226_bib22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"Del Amo","year":"2017","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2026.101226_bib23","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/aos.14042","article-title":"Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach","volume":"97","author":"Habot-Wilner","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.xops.2026.101226_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2025.100875","article-title":"Suprachoroidal injection of topotecan for retinoblastoma: a preclinical study","volume":"5","author":"Singh","year":"2025","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.xops.2026.101226_bib24","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal drug delivery to the back of the eye using hollow microneedles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm Res"},{"key":"10.1016\/j.xops.2026.101226_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048188","article-title":"Comparison of suprachoroidal drug delivery with subconjunctival and intravitreal routes using noninvasive fluorophotometry","volume":"7","author":"Tyagi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2026.101226_bib26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1167\/tvst.5.6.14","article-title":"Suprachoroidal corticosteroid administration: a novel route for local treatment of noninfectious uveitis","volume":"5","author":"Goldstein","year":"2016","journal-title":"Trans Vis Sci Technol"},{"key":"10.1016\/j.xops.2026.101226_bib27","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.oret.2017.07.013","article-title":"Suprachoroidal triamcinolone acetonide for retinal vein occlusion: results of the tanzanite study","volume":"2","author":"Campochiaro","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2026.101226_bib28","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.oret.2018.03.008","article-title":"Suprachoroidal triamcinolone acetonide for diabetic macular edema: the HULK trial","volume":"2","author":"Wykoff","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2026.101226_bib29","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye","volume":"53","author":"Patel","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101226_bib31","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1080\/03639045.2017.1342654","article-title":"Review and analysis of FDA approved drugs using lipid-based formulations","volume":"43","author":"Savla","year":"2017","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.xops.2026.101226_bib32","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1158\/1078-0432.CCR-05-0849","article-title":"Topotecan combination chemotherapy in two new rodent models of retinoblastoma","volume":"11","author":"Laurie","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.xops.2026.101226_bib33","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1167\/iovs.12-9501","article-title":"Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients","volume":"53","author":"Schaiquevich","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101226_bib34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.exer.2013.01.002","article-title":"Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma","volume":"108","author":"Buitrago","year":"2013","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2026.101226_bib35","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1097\/IAE.0000000000000253","article-title":"Ocular pharmacology of topotecan and its activity in retinoblastoma","volume":"34","author":"Schaiquevich","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.xops.2026.101226_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151343","article-title":"Topotecan delivery to the optic nerve after ophthalmic artery chemosurgery","volume":"11","author":"Taich","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2026.101226_bib37","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/bjophthalmol-2011-301450","article-title":"Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications","volume":"96","author":"Munier","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101226_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2022.109026","article-title":"Ocular and systemic toxicity of high-dose intravitreal topotecan in rabbits: implications for retinoblastoma treatment","volume":"218","author":"Del Sole","year":"2022","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2026.101226_bib39","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/bjophthalmol-2020-318529","article-title":"Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study","volume":"106","author":"Bogan","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"10.1016\/j.xops.2026.101226_bib40","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1097\/IAE.0000000000004601","article-title":"HIGH-DOSE intravitreal topotecan (100 \u03bc G\/0.1 CC) as monotherapy for recurrent\/refractory intraocular retinoblastoma in seven eyes","volume":"45","author":"Vempuluru","year":"2025","journal-title":"Retina"},{"key":"10.1016\/j.xops.2026.101226_bib41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.exer.2010.03.009","article-title":"Pharmacokinetic analysis of topotecan after intra-vitreal injection. Implications for retinoblastoma treatment","volume":"91","author":"Buitrago","year":"2010","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2026.101226_bib42","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/bjophthalmol-2015-306633","article-title":"Properties and clinical utility of topotecan fluorescence: uses for retinoblastoma","volume":"99","author":"Francis","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101226_bib43","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1167\/iovs.07-0066","article-title":"Coated microneedles for drug delivery to the eye","volume":"48","author":"Jiang","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101226_bib44","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11095-008-9756-3","article-title":"Intrascleral drug delivery to the eye using hollow microneedles","volume":"26","author":"Jiang","year":"2009","journal-title":"Pharm Res"},{"key":"10.1016\/j.xops.2026.101226_bib45","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s13346-017-0470-8","article-title":"Corneal delivery of besifloxacin using rapidly dissolving polymeric microneedles","volume":"8","author":"Bhatnagar","year":"2018","journal-title":"Drug Deliv Trans Res"},{"key":"10.1016\/j.xops.2026.101226_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118808","article-title":"Amphotericin B containing microneedle ocular patch for effective treatment of fungal keratitis","volume":"572","author":"Roy","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xops.2026.101226_bib47","article-title":"Microneedle scleral patch for minimally invasive delivery of triamcinolone to the posterior segment of eye","volume":"612","author":"Roy","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xops.2026.101226_bib48","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1080\/03639045.2020.1776317","article-title":"Microneedle ocular patch: fabrication, characterization, and ex-vivo evaluation using pilocarpine as model drug","volume":"46","author":"Roy","year":"2020","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.xops.2026.101226_bib49","doi-asserted-by":"crossref","first-page":"740","DOI":"10.4103\/ijo.IJO_866_19","article-title":"Intra-arterial chemotherapy in retinoblastoma\u2014a paradigm change","volume":"67","author":"Manjandavida","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101226_bib50","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1208\/s12249-023-02516-9","article-title":"Ocular drug delivery: a comprehensive review","volume":"24","author":"Ahmed","year":"2023","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xops.2026.101226_bib51","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000524919","article-title":"Emerging new therapeutics for retinoblastoma","volume":"8","author":"Raval","year":"2022","journal-title":"Ocul Oncol Pathol"},{"key":"10.1016\/j.xops.2026.101226_bib52","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1167\/iovs.07-0653","article-title":"Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma","volume":"49","author":"Tsui","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101226_bib53","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s43094-024-00587-4","article-title":"Nanotechnology-based strategies overcoming the challenges of retinoblastoma: a comprehensive overview and future perspectives","volume":"10","author":"Hatem","year":"2024","journal-title":"Future J Pharm Sci"},{"key":"10.1016\/j.xops.2026.101226_bib54","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jcjo.2024.06.007","article-title":"Digital retinoblastoma documentation supports care and research","volume":"60","author":"Gallie","year":"2025","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101226_bib55","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s13346-016-0332-9","article-title":"Rapidly dissolving polymeric microneedles for minimally invasive intraocular drug delivery","volume":"6","author":"Thakur","year":"2016","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.xops.2026.101226_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114209","article-title":"Polymeric microneedles for the eye: an overview of advances and ocular applications for minimally invasive drug delivery","volume":"197","author":"Mulkutkar","year":"2024","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xops.2026.101226_bib57","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11095-024-03658-6","article-title":"Progress in the application of microneedles in eye disorders and the proposal of the upgraded microneedle with spinule","volume":"41","author":"Yang","year":"2024","journal-title":"Pharm Res"},{"key":"10.1016\/j.xops.2026.101226_bib58","article-title":"Ocular delivery of cyclosporine A using dissolvable microneedle contact lens","volume":"70","author":"Datta","year":"2022","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.xops.2026.101226_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124614","article-title":"Deferasirox nanosuspension loaded dissolving microneedles for ocular drug delivery","volume":"664","author":"Faizi","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xops.2026.101226_bib60","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1080\/09205063.2024.2380129","article-title":"Development of itraconazole ocular delivery system using \u03b2-cyclodextrin complexation incorporated into dissolving microneedles for potential improvement treatment of fungal keratitis","volume":"35","author":"Putri","year":"2024","journal-title":"J Biomater Sci Polym Ed"},{"key":"10.1016\/j.xops.2026.101226_bib61","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jconrel.2024.05.013","article-title":"Hollow microneedles for ocular drug delivery","volume":"371","author":"Gade","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.xops.2026.101226_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121305","article-title":"Microneedle scleral patch for minimally invasive delivery of triamcinolone to the posterior segment of eye","volume":"612","author":"Roy","year":"2022","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xops.2026.101226_bib63","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/17425247.2016.1218460","article-title":"Minimally invasive microneedles for ocular drug delivery","volume":"14","author":"Thakur Singh","year":"2017","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.xops.2026.101226_bib64","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s13346-021-01032-2","article-title":"Rapidly dissolving microneedle patch of amphotericin B for intracorneal fungal infections","volume":"12","author":"Albadr","year":"2022","journal-title":"Drug Deliv Trans Res"},{"key":"10.1016\/j.xops.2026.101226_bib65","article-title":"Self-implantable core-shell microneedle patch for long-acting treatment of Keratitis via programmed drug release","volume":"20","author":"Jiang","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.xops.2026.101226_bib66","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1089\/jop.2021.0089","article-title":"Sustained release biodegradable microneedles of difluprednate for delivery to posterior eye","volume":"38","author":"Shelley","year":"2022","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.xops.2026.101226_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/srep33796","article-title":"Anterior eye tissue morphology: scleral and conjunctival thickness in children and young adults","volume":"6","author":"Read","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2026.101226_bib68","first-page":"320","article-title":"Distribution of aqueous solutions injected suprachoroidally (SC) in rabbits","volume":"61","author":"Nork","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526001648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526001648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:16:03Z","timestamp":1785892563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914526001648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":68,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666914526001648"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101226","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topotecan Microneedle Scleral Patch: A Transscleral Drug Delivery Study for Retinoblastoma","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101226","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101226"}}